is no clinical prototype unconditionally warranting treatment with MTX, rather the use of this drug should be discussed on an individual basis. In clinical practice, MTX may be considered for example in female patients The panel also reached a consensus that MTX should be considered in patients who have relapsed (either on or off GCs), cases without significant response to GC or patients experiencing GC-related adverse events. The group further agreed that MTX may be used with oral or i.m. GC